Is This How Drugmakers Will Kill Biosimilars?
Pfizer (NYSE: PFE) has filed a lawsuit accusing Johnson & Johnson (NYSE: JNJ) of strong-arming insurers into excluding its Remicade biosimilar, Inflectra, from their reimbursement lists. If drugmakers start to employ this strategy widely, it could have big implications on the peak market potential for biosimilars industrywide.
In this clip from the Motley Fool's Industry Focus: Healthcare podcast, analyst Michael Douglass and contributor Todd Campbell offer some insights into Pfizer's dispute with Johnson & Johnson, and discuss more broadly what the suit may mean to investors.
A full transcript follows the video.
Source: Fool.com
Pfizer Inc. Stock
€21.71
0.790%
With 15 Buy predictions and only 2 Sell predictions the community sentiment for the stock is positive.
With a target price of 29 € there is a positive potential of 33.61% for Pfizer Inc. compared to the current price of 21.71 €.
